Special Issue "Circulating Biomarkers"

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: 10 April 2020.

Special Issue Editor

Assoc. Prof. Therese Becker
E-Mail Website
Guest Editor
1. Centre for Circulating Tumour Cell Diagnostics and Research, Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia
2. School of Medicine, University of Western Sydney, Liverpool, NSW, Australia
3. South Western Medical School, University of New South Wales, Liverpool, Australia
4. CONCERT-Translational Cancer Research Centre, NSW, Australia
Tel. 61-2-87389033
Interests: biomarker, liquid biopsy, circulating tumour cells (CTCs), circulating tumor nucleic acids (ctDNA), ddPCR, melanoma, prostate cancer, lung cancer, brain cancer, personalized medicine

Special Issue Information

Dear Colleagues,

Biomarkers are biological indicators, and in medicine, they potentially are able to dictate the best patient management and allow for personalised therapy. In recent years, we have been experiencing a revolution of technologies to detect and analyse various biomarkers down to their biochemical and biophysical level. A lot of emphasis is on circulating biomarkers because they can be examined from relatively simple, non-invasive liquid biopsies. Circulating biomarkers carry enormous potential, especially for diseases like cancer, where the cancer itself, in part due to the selective pressure of medication, evolves and changes over time. Liquid biopsies can be taken repeatedly for diagnostic and prognostic purposes and to monitor response to therapy or developing resistance.

In this Special Circulating Biomarkers Issue, we will explore how technologies are refined to investigate established and novel biomarkers from liquid biopsies. We aim to determine and review how well these techniques are implemented in the clinics, with future perspectives on how the research field and clinical applications may develop. Last but not least, we will look at how circulating biomarkers can translate into patient management and disease outcomes and how well they compare on a health economic level with current alternatives.

The science considered here is inclusive and does not aim to restrict authors but rather to open up the Special Issue to as wide an audience as possible. Technical articles progressing recent advances in methodologies are welcome, while biological and medical studies that translate understanding of circulating biomarkers into clinical settings are equally encouraged.

Assoc. Prof.Therese Becker
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Liquid biopsy
  • Circulating tumour cell (CTC)
  • Single cell analysis
  • Circulating tumour nucleic acid (ctNA, including ctDNA, ctRNA, ct-mirRNA)
  • Exosomes
  • Extracellular vesicles
  • Plasma/serum cancer antigens
  • Circulating protein markers
  • Blood-based biomarker
  • Circulating lipid markers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Open AccessArticle
Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection
Appl. Sci. 2019, 9(22), 4784; https://doi.org/10.3390/app9224784 - 08 Nov 2019
Clinical follow-up aided by changes in the expression of circulating microRNAs (miRs) may improve prognostication of pancreatic ductal adenocarcinoma (PDAC) patients. Changes in 179 circulating miRs due to cancer progression in the transgenic KrasG12D/+; Trp53R172H/+; P48-Cre (KPC) animal model [...] Read more.
Clinical follow-up aided by changes in the expression of circulating microRNAs (miRs) may improve prognostication of pancreatic ductal adenocarcinoma (PDAC) patients. Changes in 179 circulating miRs due to cancer progression in the transgenic KrasG12D/+; Trp53R172H/+; P48-Cre (KPC) animal model of PDAC were analyzed for serum miRs that are altered in metastatic disease. In addition, expression levels of 250 miRs were profiled before and after pancreaticoduodenectomy in the serum of two patients with resectable PDAC with different progression free survival (PFS) and analyzed for changes indicative of PDAC recurrence after resection. Three miRs that were upregulated ≥3-fold in progressive PDAC in both mice and patients were selected for validation in 26 additional PDAC patients before and after resection. We found that high serum miR-125b-5p and miR-99a-5p levels after resection are significantly associated with shorter PFS (HR 1.34 and HR 1.73 respectively). In situ hybridization for miR detection in the paired resected human PDAC tissues showed that miR-125b-5p and miR-99a-5p are highly expressed in inflammatory cells in the tumor stroma, located in clusters of CD79A expressing cells of the B-lymphocyte lineage. In conclusion, we found that circulating miR-125b-5p and miR-99a-5p are potential immune-cell related prognostic biomarkers in PDAC patients after surgery. Full article
(This article belongs to the Special Issue Circulating Biomarkers)
Show Figures

Figure 1

Back to TopTop